Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged new theophine GLP-1 receptor agonists reported to be useful for the treatment of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, obesity, glucose intolerance, dyslipidemia, hyperinsulinemia and insulin resistance.
Eccogene (Shanghai) Co. Ltd. has presented new GLP-1 receptor agonists reported to be useful for the treatment of diabetes, obesity, atherosclerosis, hypertension, stroke, Parkinson’s disease, diabetic kidney disease and liver disease.
Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharmaceutical Tech Co. Ltd. have divulged new polycyclic lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of small-cell lung cancer (SCLC).
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new fused tetracyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1, MEKKK1) inhibitors reported to be useful for the treatment of cancer, diabetes, inflammation, infections, neurodegeneration and autoimmune, cardiovascular and reproductive disorders.
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis.
Adlai Nortye Ltd. has described mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
RSS